Stephen G. Noorduyn

Exacerbations and Healthcare Burden of COPD with Type 2 Inflammation: US Claims Analysis

IF4

2026-08-220

2型炎症型COPD的急性加重与医疗负担：美国索赔数据分析

International Journal of Chronic Obstructive Pulmonary Disease

IF3.1

2026-08-130

Response to: Letter to the Editor Regarding “Comparative Effectiveness of FF/1 UMEC/VI and BUD/GLY/FORM in Patients with COPD Stepping Up From Dual Therapy”

FF/UMEC/VI and BUD/GLY/FORM in Patients with COPD Stepping Up from Dual Therapy Stratified by Exacerbations and Prior Dual Therapy: A Subgroup Analysis of a Comparative Effectiveness Study

IF4

2026-01-220

OAAI

Evaluating Asthma Clinical Remission with Inhaled Therapy: Post Hoc Analyses of CAPTAIN

IF4

2026-01-190

OAAI

吸入疗法治疗哮喘临床缓解的评估：CAPTAIN研究的事后分析

TETRIS - Prospective study to observe clinical outcomes of triple therapy in COPD patients: Up to 12 months interim analysis

IF4

2025-12-240

OAAI

TETRIS - 前瞻性研究观察COPD患者三联疗法的临床结局：为期12个月的期中分析

Respiratory Medicine

IF3.1

2025-12-010

OAAI

Exacerbation Reduction in Patients with Asthma Following Escalation to FF/UMEC/VI from ICS/LABA: Retrospective Cohort Study

PULMONARY THERAPY

IF3

2025-10-010

OAAI

Comparative Effectiveness of FF/UMEC/VI and BUD/GLY/FORM in Patients with COPD Stepping Up From Dual Therapy

比较FF/UMEC/VI与BUD/GLY/FORM在从双重疗法升级治疗的COPD患者中的疗效

Real-World Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol Initiation in Japanese Patients with Asthma Previously on Inhaled Corticosteroid/Long-Acting β2-Agonist Therapy: A Retrospective Cohort Study

IF4

2025-07-070

富马酸氟替卡松/乌美溴铵/维兰特罗在日本哮喘患者中的真实世界初始疗效：一项回顾性队列研究（此前接受吸入性糖皮质激素/长效β2激动剂治疗者）

JOURNAL OF CLINICAL MEDICINE

IF2.9

2025-04-090

Comparative Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol and Budesonide/Glycopyrrolate/Formoterol Fumarate among US Patients with Chronic Obstructive Pulmonary Disease

Medicare Advantage Population in the United States: Outcomes of Patients with Asthma Treated with ICS/LABA Before and After Initiation with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)

IF4

2024-12-280

OAAI

Adherence and Persistence with Single-Inhaler Triple Therapy Among Patients with COPD Using Commercial and Medicare Advantage US Health Plan Claims Data

IF4

2024-12-230

OAAI

Characteristics of patients meeting the components of clinical remission: CAPTAIN post hoc analysis

IF4

2024-12-051

OAAI

Is single-inhaler triple therapy cost-effective versus multiple-inhaler triple therapy for COPD in Germany? The INTREPID trial

IF21

2024-10-300

PRE

Patients' perspectives and perceptions of asthma clinical remission: A global view

IF21

2024-10-300

PRE

Impact of varying lung function threshold on clinical remission in asthma with FF/UMEC/VI: CAPTAIN post hoc analysis

IF21

2024-10-300

PRE

Assessment of the components of clinical remission with moderate-severe asthma after 24-52 weeks of treatment: CAPTAIN post hoc analysis

IF21

2024-10-300

PRE

Fluticasone Furoate/Umeclidinium/Vilanterol Initiation Following a COPD Exacerbation: Benefits of Prompt Initiation on COPD Outcomes

IF21

2024-10-300

PRE

Outcomes of Patients with COPD Treated with ICS/LABA Before and After Initiation of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)

IF4

2024-10-250

OAAI